Study on the effectiveness of COVID-19 measures in the Netherlands The measures implemented in the Netherlands during the COVID-19 crisis were effective against the spread of the SARS-CoV-2 virus. This is the outcome of a study conducted by RIVM.
Air pollution increases risk of infection and severity of illness from COVID-19 People who live in areas with poor air quality are more likely to become infected with SARS-CoV-2. Moreover, the symptoms of COVID-19 are more severe, leading to more hospitalisations and deaths. This is the outcome of a study conducted by RIVM, Utrecht University, Wageningen University & Research and the Netherlands Municipal Public Health Services and Medical Assistance in Accidents and Disasters.
RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Number of tuberculosis patients in the Netherlands increased in 2023 compared to 2022 In 2023, 710 people in the Netherlands were diagnosed with tuberculosis (TB). This was 12 per cent more than in 2022, when there were 634. In 2023, 471 patients had pulmonary TB. Of these 417 patients, 213 had open TB – the most contagious type.
Start of rotavirus vaccinations This week saw the start of babies being vaccinated against the rotavirus. This vaccination is included in the Dutch National Immunisation Programme as of this year. All parents of babies born on or after 1 January 2024 will receive an invitation for this.
More than 2.7 million COVID-19 vaccinations administered in the 2023 autumn round In the 2023 autumn round, more than 2,731,000 people in the Netherlands received a COVID-19 vaccination. Vaccination coverage for people over 60 is currently 50.5%. Vaccination coverage varies by age group and region. COVID-19 vaccination was available until 22 December 2023.
Protection against rotavirus included in National Immunisation Programme from 2024 From 2024, rotavirus vaccination will be included in the National Immunisation Programme (NIP). Rotavirus can cause severe diarrhoea and dehydration in babies, in some cases requiring them to be hospitalised.
Booster vaccinations reduced risk of death from COVID-19 in 2022 Booster vaccinations reduced the risk of dying from COVID-19 in 2022. The risk of death from other causes was also lower for people who had a booster jab than for people without a booster jab. These findings are from research by RIVM.
COVID-19 pandemic made me miss out on a key stage of my life, young people claim Young people aged 12–25 feel that the COVID-19 pandemic made them miss out on a key stage of their lives. They have indicated that important milestones, such as graduation ceremonies or the start of student life, passed them by. This is evident from the latest quarterly study conducted by the Network for Health Research in Disasters.